Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001140361-21-029585
Filing Date
2021-08-27
Accepted
2021-08-27 16:37:19
Documents
14
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q/A brhc10028424_10qa.htm   iXBRL 10-Q/A 41527
2 EXHIBIT 31.1 brhc10028424_ex31-1.htm EX-31.1 9104
3 EXHIBIT 31.2 brhc10028424_ex31-2.htm EX-31.2 9274
  Complete submission text file 0001140361-21-029585.txt   232016

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA cycn-20210331.xsd EX-101.SCH 3926
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE cycn-20210331_lab.xml EX-101.LAB 27009
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cycn-20210331_pre.xml EX-101.PRE 19092
7 EXTRACTED XBRL INSTANCE DOCUMENT brhc10028424_10qa_htm.xml XML 5683
Mailing Address 301 BINNEY STREET CAMBRIDGE MA 02142
Business Address 301 BINNEY STREET CAMBRIDGE MA 02142 617-621-7722
Cyclerion Therapeutics, Inc. (Filer) CIK: 0001755237 (see all company filings)

EIN.: 831895370 | State of Incorp.: MA | Fiscal Year End: 1231
Type: 10-Q/A | Act: 34 | File No.: 001-38787 | Film No.: 211219433
SIC: 2834 Pharmaceutical Preparations